Hepatotoxicity of Keppra (Levetiracetam) and Lacosamide
Neither Keppra (levetiracetam) nor lacosamide are significantly hepatotoxic, and both are specifically recommended as preferred antiepileptic drugs in patients with liver disease precisely because they undergo minimal hepatic metabolism. 1, 2, 3, 4
Evidence from Guidelines and Drug Labels
Multiple high-quality guidelines consistently identify levetiracetam and lacosamide as safe options with minimal hepatotoxicity:
The 2021 EANO-ESMO neuro-oncology guidelines explicitly state that "levetiracetam and lamotrigine are preferred options of first choice because of their efficacy and overall good tolerability," while enzyme-inducing anticonvulsants should be avoided 1
The 2022 SNO brain metastases consensus recommends that "agents that do not significantly impact hepatic metabolizing enzymes, such as levetiracetam, lacosamide, or lamotrigine are generally preferred" 2
The 2017 comprehensive review on antiepileptic drugs and liver disease categorically states that "newer antiepileptic drugs without, or with minimal, hepatic metabolism, such as levetiracetam, lacosamide, topiramate, gabapentin, and pregabalin should be used as first-line therapy" in patients with liver disease 4
The FDA drug label for Keppra confirms minimal hepatotoxicity: "There were no meaningful changes in mean liver function tests (LFT) in controlled trials in adult or pediatric patients; lesser LFT abnormalities were similar in drug and placebo treated patients in controlled trials (1.4%)" 5
Rare Case Reports vs. Clinical Reality
While isolated case reports exist documenting hepatotoxicity with both drugs 6, 7, 8, 9, these represent extremely rare events:
Levetiracetam: A 2022 systematic review found only 21 documented cases of liver injury over 22 years (1999-2021), with median onset at 19 days 7. The FDA label notes that less than 1% of patients experience transient liver enzyme elevations 5
Lacosamide: Even fewer cases exist in the literature, with hepatotoxicity described as a rare and unexpected side effect 8
One case report described combined toxicity with both drugs, but this involved massive intentional overdose (8g lacosamide + 62.5g levetiracetam) 9
Clinical Implications
Both drugs are specifically chosen for patients at risk of hepatotoxicity:
- They are recommended over valproic acid, phenytoin, and felbamate, which have well-recognized hepatotoxic potential 4
- They can be safely used in patients with chronic, stable liver disease (e.g., nonalcoholic fatty liver disease) 10
- For status epilepticus in patients with liver disease, levetiracetam and lacosamide (both available IV) are recommended as second-line therapies 4
Monitoring Recommendations
Routine liver function monitoring is not recommended for either drug 5. The FDA label states: "Although most laboratory tests are not systematically altered with KEPPRA treatment, there have been relatively infrequent abnormalities seen in hematologic parameters and liver function tests" 5
However, if symptoms suggesting hepatotoxicity develop (nausea, abdominal pain, jaundice), liver function tests should be obtained 10.
Common Pitfall to Avoid
Do not confuse these drugs with older antiepileptic medications like valproic acid (associated with hepatotoxicity in ~2% of patients and contraindicated in pregnancy due to teratogenicity) 11, 3 or phenytoin and carbamazepine (enzyme-inducing drugs with significant drug interactions and hepatic metabolism) 1, 2.